{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:20:45Z","timestamp":1792200045819,"version":"4.4.0"},"reference-count":206,"publisher":"Sociedade Brasileira de Cardiologia","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.36660\/abc.20210718","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T19:18:07Z","timestamp":1632251887000},"page":"561-598","source":"Crossref","is-referenced-by-count":85,"title":["Posicionamento sobre Diagn\u00f3stico e Tratamento da Amiloidose Card\u00edaca \u2013 2021"],"prefix":"10.36660","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6553-8387","authenticated-orcid":false,"given":"Marcus V.","family":"Sim\u00f5es","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-8805","authenticated-orcid":false,"given":"Fabio","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-5638","authenticated-orcid":false,"given":"Fabiana G.","family":"Marcondes-Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-8838","authenticated-orcid":false,"given":"Edileide de Barros","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-393X","authenticated-orcid":false,"given":"Luis Eduardo P.","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-2752","authenticated-orcid":false,"given":"Fernando","family":"Bacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-9743","authenticated-orcid":false,"given":"Silvia Marinho Martins","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0894-1131","authenticated-orcid":false,"given":"Sandrigo","family":"Mangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8579-4158","authenticated-orcid":false,"given":"Andr\u00e9ia","family":"Biolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5702-210X","authenticated-orcid":false,"given":"Luis","family":"Beck-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-3486","authenticated-orcid":false,"given":"Roberta Shcolnik","family":"Szor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Junior","given":"Wilson","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-4937","authenticated-orcid":false,"given":"Acary Souza Bulle","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-2236","authenticated-orcid":false,"given":"M\u00e1rcia Waddington","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-7779","authenticated-orcid":false,"given":"Bruno Vaz Kerges","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-2055","authenticated-orcid":false,"given":"Ludhmila Abrah\u00e3o","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4894-6116","authenticated-orcid":false,"given":"Aurora Felice Castro","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-2485","authenticated-orcid":false,"given":"Felix Jos\u00e9 Alvarez","family":"Ramires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-5186","authenticated-orcid":false,"suffix":"Filho","given":"Otavio Rizzi","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-8165","authenticated-orcid":false,"given":"Andr\u00e9","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraim Masciarelli Francisco","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-3344","authenticated-orcid":false,"given":"Carlos Eduardo","family":"Rochitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Luiz Campos","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-9413","authenticated-orcid":false,"given":"Cl\u00e1udio Tinoco","family":"Mesquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso Dario","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Soares-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2526-0656","authenticated-orcid":false,"given":"Minna Moreira Dias","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-6754","authenticated-orcid":false,"suffix":"Junior","given":"Wilson","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Junior","given":"Marcelo I\u00f3rio","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Westerlund","family":"Montera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Dantas Tavares de","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Marques e","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Manoel Marques","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Neto","given":"Arist\u00f3teles Comte de","family":"Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato Delascio","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7432-576X","authenticated-orcid":false,"given":"Diane Xavier de","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denizar","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-8862","authenticated-orcid":false,"given":"Jos\u00e9 Francisco Kerr","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6014-5533","authenticated-orcid":false,"given":"Manoel Fernandes","family":"Canesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-1279","authenticated-orcid":false,"given":"Glaucia Maria Moraes de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7452-3870","authenticated-orcid":false,"given":"Evandro Tinoco","family":"Mesquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22636","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"issue":"2-3","key":"key20210921151803_B1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/jsbi.2000.4221","article-title":"Review: history of the amyloid fibril","volume":"130","author":"Sipe","year":"2000","unstructured":"1. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol. 2000;130(2-3):88-98.","journal-title":"J Struct Biol"},{"issue":"4","key":"key20210921151803_B2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","unstructured":"2. Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215-9.","journal-title":"Amyloid"},{"issue":"12","key":"key20210921151803_B3","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy","volume":"68","author":"Falk","year":"2016","unstructured":"3. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68(12):1323-41.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"key20210921151803_B4","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","unstructured":"4. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286-300.","journal-title":"Circulation"},{"issue":"11","key":"key20210921151803_B5","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","unstructured":"5. Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 2013;52(11):1913-26.","journal-title":"Biochemistry"},{"issue":"6","key":"key20210921151803_B6","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1096\/fj.11-189571","article-title":"Why are some amyloidoses systemic? Does hepatic \u201cchaperoning at a distance\u201d prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?","volume":"26","author":"Buxbaum","year":"2012","unstructured":"6. Buxbaum JN, Tagoe C, Gallo G, Walker JR, Kurian S, Salomon DR. Why are some amyloidoses systemic? Does hepatic \u201cchaperoning at a distance\u201d prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J. 2012;26(6):2283-93.","journal-title":"FASEB J"},{"issue":"2","key":"key20210921151803_B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrcardio.2014.165","article-title":"Pathophysiology and treatment of cardiac amyloidosis","volume":"12","author":"Gertz","year":"2015","unstructured":"7. Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12(2):91-102.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"key20210921151803_B8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biomedicines7010011","article-title":"Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights","volume":"7","author":"Koike","year":"2019","unstructured":"8. Koike H, Katsuno M. Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights. Biomedicines. 2019;7(1):11.","journal-title":"Biomedicines"},{"issue":"22","key":"key20210921151803_B9","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","unstructured":"9. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-91.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20210921151803_B10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.currproblcancer.2016.11.004","article-title":"Light-chain cardiac amyloidosis","volume":"41","author":"Mankad","year":"2017","unstructured":"10. Mankad AK, Sesay I, Shah KB. Light-chain cardiac amyloidosis. Curr Probl Cancer. 2017;41(2):144-56.","journal-title":"Curr Probl Cancer"},{"issue":"10038","key":"key20210921151803_B11","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","unstructured":"11. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641-54.","journal-title":"Lancet"},{"issue":"1","key":"key20210921151803_B12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review","volume":"324","author":"Gertz","year":"2020","unstructured":"12. Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324(1):79-89.","journal-title":"JAMA"},{"issue":"3","key":"key20210921151803_B13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","unstructured":"13. Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289(3):268-92.","journal-title":"J Intern Med"},{"issue":"3","key":"key20210921151803_B14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies","volume":"22","author":"Milandri","year":"2020","unstructured":"14. Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020;22(3):507-15.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"key20210921151803_B15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice","volume":"7","author":"Witteles","year":"2019","unstructured":"15. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019;7(8):709-16.","journal-title":"JACC Heart Fail"},{"issue":"3","key":"key20210921151803_B16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amjcard.2011.03.069","article-title":"Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men","volume":"108","author":"Jacobson","year":"2011","unstructured":"16. Jacobson D, Tagoe C, Schwartzbard A, Shah A, Koziol J, Buxbaum J. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Am J Cardiol. 2011;108(3):440-4.","journal-title":"Am J Cardiol"},{"key":"key20210921151803_B17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","unstructured":"17. Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr OB, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29 Suppl 1:S3-S13.","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"key20210921151803_B18","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","unstructured":"18. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O\u2019Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-22.","journal-title":"Blood"},{"issue":"24","key":"key20210921151803_B19","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","unstructured":"19. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-12.","journal-title":"Circulation"},{"issue":"1","key":"key20210921151803_B20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis","volume":"140","author":"Lane","year":"2019","unstructured":"20. Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019;140(1):16-26.","journal-title":"Circulation"},{"issue":"38","key":"key20210921151803_B21","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","unstructured":"21. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94.","journal-title":"Eur Heart J"},{"issue":"4","key":"key20210921151803_B22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","unstructured":"22. Cornwell GG, 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75(4):618-23.","journal-title":"Am J Med"},{"issue":"3","key":"key20210921151803_B23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","unstructured":"23. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232-9.","journal-title":"Ann Med"},{"issue":"2","key":"key20210921151803_B24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1590\/0004-282x20180156","article-title":"Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS)","volume":"77","author":"Cruz","year":"2019","unstructured":"24. Cruz MW, Pinto MV, Pinto LF, Gervais R, Dias M, Perez C, et al. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS). Arq Neuropsiquiatr. 2019;77(2):96-100.","journal-title":"Arq Neuropsiquiatr"},{"issue":"6","key":"key20210921151803_B25","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","unstructured":"25. Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, et al. Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail. 2019;12(6):e005407.","journal-title":"Circ Heart Fail"},{"issue":"10","key":"key20210921151803_B26","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium","volume":"32","author":"Lousada","year":"2015","unstructured":"26. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32(10):920-8.","journal-title":"Adv Ther"},{"issue":"1","key":"key20210921151803_B27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","unstructured":"27. Adams D, Polydefkis M, Gonzalez-Duarte A, Wixner J, Kristen AV, Schmidt HH, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021;20(1):49-59.","journal-title":"Lancet Neurol"},{"issue":"12","key":"key20210921151803_B28","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plante-Bordeneuve","year":"2011","unstructured":"28. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086-97.","journal-title":"Lancet Neurol"},{"issue":"9","key":"key20210921151803_B29","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","unstructured":"29. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036-43.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20210921151803_B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2019.05.030","article-title":"Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry","volume":"403","author":"Pinto","year":"2019","unstructured":"30. Pinto MV, Pinto LF, Dias M, Rosa RS, Mundayat R, Pedrosa RC, et al. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry. J Neurol Sci. 2019;403:1-6.","journal-title":"J Neurol Sci"},{"issue":"7","key":"key20210921151803_B31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","unstructured":"31. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398-408.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"key20210921151803_B32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JND-180371","article-title":"Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis","volume":"6","author":"Kapoor","year":"2019","unstructured":"32. Kapoor M, Rossor AM, Laura M, Reilly MM. Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis. J Neuromuscul Dis. 2019;6(2):189-99.","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"key20210921151803_B33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41431-019-0337-1","article-title":"Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data","volume":"27","author":"Lahuerta-Pueyo","year":"2019","unstructured":"33. Lahuerta-Pueyo CL, Tubar Arregui MA, Gracia- Gutierrez AG, Buena Juana E, Guill\u00e9n SM. Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data. Eur J Hum Genet. 2019;27(5):783-91.","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"key20210921151803_B34","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.3390\/ijms20122982","article-title":"Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases","volume":"20","author":"Park","year":"2019","unstructured":"34. Park GY, Jamerlan A, Shim KH, An SSA. Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases. Int J Mol Sci. 2019;20(12):2982.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"key20210921151803_B35","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis","volume":"12","author":"Maurer","year":"2019","unstructured":"35. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019;12(9):e006075.","journal-title":"Circ Heart Fail"},{"key":"key20210921151803_B36","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"Obici","year":"2016","unstructured":"36. Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29 Suppl 1:S27-35.","journal-title":"Curr Opin Neurol"},{"issue":"14","key":"key20210921151803_B37","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis","volume":"135","author":"Maurer","year":"2017","unstructured":"37. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357-77.","journal-title":"Circulation"},{"issue":"2","key":"key20210921151803_B38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","unstructured":"38. Castano A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20(2):163-78.","journal-title":"Heart Fail Rev"},{"issue":"21","key":"key20210921151803_B39","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/heartjnl-2012-301924","article-title":"Cardiac transthyretin amyloidosis","volume":"98","author":"Dungu","year":"2012","unstructured":"39. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart. 2012;98(21):1546-54.","journal-title":"Heart"},{"issue":"10","key":"key20210921151803_B40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","unstructured":"40. Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528-40.","journal-title":"Arch Cardiovasc Dis"},{"issue":"2","key":"key20210921151803_B41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","unstructured":"41. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113-22.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"key20210921151803_B42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","unstructured":"42. Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015;20(2):117-24.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"key20210921151803_B43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)","volume":"110","author":"Yilmaz","year":"2021","unstructured":"43. Yilmaz A, Bauersachs J, Bengel F, Buchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110(4):479-506.","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"key20210921151803_B44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","unstructured":"44. Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23(1):58-63.","journal-title":"Amyloid"},{"issue":"10","key":"key20210921151803_B45","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis","volume":"318","author":"Geller","year":"2017","unstructured":"45. Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017;318(10):962-3.","journal-title":"JAMA"},{"issue":"6","key":"key20210921151803_B46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","unstructured":"46. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-96.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20210921151803_B47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Conceicao","year":"2016","unstructured":"47. Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5-9.","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"key20210921151803_B48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","article-title":"Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm","volume":"13","author":"Sekijima","year":"2018","unstructured":"48. Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"key20210921151803_B49","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic Resonance in Transthyretin Cardiac Amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","unstructured":"49. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017;70(4):466-77.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20210921151803_B50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2020.11.007","article-title":"Concomitant Cardiac Amyloidosis in Severe Aortic Stenosis: The Trojan Horse?","volume":"77","author":"Pibarot","year":"2021","unstructured":"50. Pibarot P, Lancellotti P, Narula J. Concomitant Cardiac Amyloidosis in Severe Aortic Stenosis: The Trojan Horse? J Am Coll Cardiol. 2021;77(2):140-3.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"key20210921151803_B51","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","unstructured":"51. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014;114(7):1089-93.","journal-title":"Am J Cardiol"},{"issue":"18","key":"key20210921151803_B52","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","unstructured":"52. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840-9.","journal-title":"Circulation"},{"issue":"1","key":"key20210921151803_B53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9149(82)90270-3","article-title":"Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation","volume":"49","author":"Carroll","year":"1982","unstructured":"53. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation. Am J Cardiol. 1982;49(1):9-13.","journal-title":"Am J Cardiol"},{"issue":"1","key":"key20210921151803_B54","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","unstructured":"54. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7-e22.","journal-title":"Circulation"},{"issue":"1","key":"key20210921151803_B55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2019","unstructured":"55. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1-64.","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"key20210921151803_B56","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0735-1097(00)00908-6","article-title":"Doppler-derived dP\/dt and -dP\/dt predict survival in congestive heart failure","volume":"36","author":"Kolias","year":"2000","unstructured":"56. Kolias TJ, Aaronson KD, Armstrong WF. Doppler-derived dP\/dt and -dP\/dt predict survival in congestive heart failure. J Am Coll Cardiol. 2000;36(5):1594-9.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20210921151803_B57","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.echo.2014.11.003","article-title":"Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/Industry Task Force to standardize deformation imaging","volume":"28","author":"Voigt","year":"2015","unstructured":"57. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr. 2015;28(2):183-93.","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"key20210921151803_B58","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2016.12.012","article-title":"A Test in Context: Myocardial Strain Measured by Speckle-Tracking Echocardiography","volume":"69","author":"Collier","year":"2017","unstructured":"58. Collier P, Phelan D, Klein A. A Test in Context: Myocardial Strain Measured by Speckle-Tracking Echocardiography. J Am Coll Cardiol. 2017;69(8):1043-56.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"key20210921151803_B59","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.echo.2020.06.001","article-title":"Left Ventricular Pressure Strain-Derived Myocardial Work at Rest and during Exercise in Patients with Cardiac Amyloidosis","volume":"33","author":"Pagourelias","year":"2020","unstructured":"59. Pagourelias ED, Vassilikos VP, Voigt JU. Left Ventricular Pressure Strain-Derived Myocardial Work at Rest and during Exercise in Patients with Cardiac Amyloidosis. J Am Soc Echocardiogr. 2020;33(10):1295-6.","journal-title":"J Am Soc Echocardiogr"},{"issue":"10","key":"key20210921151803_B60","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1253\/circj.CJ-17-1392","article-title":"Myocardial Deformation Analysis and Late-Gadolinium Enhancement: Important Markers of Cardiac Amyloidosis Involvement That Can Masquerade as a False-Negative Diagnosis","volume":"82","author":"Di Bella","year":"2018","unstructured":"60. Di Bella G, Pizzino F. Myocardial Deformation Analysis and Late-Gadolinium Enhancement: Important Markers of Cardiac Amyloidosis Involvement That Can Masquerade as a False-Negative Diagnosis. Circ J. 2018;82(10):2687.","journal-title":"Circ J"},{"issue":"7 Pt 1","key":"key20210921151803_B61","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jcmg.2018.06.016","article-title":"Relative Apical Sparing of Myocardial Longitudinal Strain Is Explained by Regional Differences in Total Amyloid Mass Rather Than the Proportion of Amyloid Deposits","volume":"12","author":"Bravo","year":"2019","unstructured":"61. Bravo PE, Fujikura K, Kijewski MF, Jerosch-Herold M, Jacob S, El-Sady MS, et al. Relative Apical Sparing of Myocardial Longitudinal Strain Is Explained by Regional Differences in Total Amyloid Mass Rather Than the Proportion of Amyloid Deposits. JACC Cardiovasc Imaging. 2019;12(7 Pt 1):1165-73.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7 Pt 1","key":"key20210921151803_B62","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jcmg.2018.07.007","article-title":"Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis: Is it Just Amyloid Infiltration?","volume":"12","author":"Rapezzi","year":"2019","unstructured":"62. Rapezzi C, Fontana M. Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis: Is it Just Amyloid Infiltration? JACC Cardiovasc Imaging. 2019;12(7 Pt 1):1174-6.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"key20210921151803_B63","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.echo.2019.03.005","article-title":"Role of Right Ventricular Strain Measured by Two-Dimensional Echocardiography in the Diagnosis of Cardiac Amyloidosis","volume":"32","author":"Monivas Palomero","year":"2019","unstructured":"63. Monivas Palomero V, Durante-Lopez A, Sanabria MT, Cubero JS, Gonzalez-Mirelis J, Lopez-Ibor JV, et al. Role of Right Ventricular Strain Measured by Two-Dimensional Echocardiography in the Diagnosis of Cardiac Amyloidosis. J Am Soc Echocardiogr. 2019;32(7):845-53 e1.","journal-title":"J Am Soc Echocardiogr"},{"key":"key20210921151803_B64","article-title":"Phasic left atrial strain analysis to discriminate cardiac amyloidosis in patients with unclear thick heart pathology","author":"Brand","year":"2020","unstructured":"64. Brand A, Frumkin D, Hubscher A, Dreger H, Stangl K, Baldenhofer G, et al. Phasic left atrial strain analysis to discriminate cardiac amyloidosis in patients with unclear thick heart pathology. Eur Heart J Cardiovasc Imaging. 2020 Apr 3;jeaa043. Doi 10.1093\/ehjci\/jeaa043","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"key20210921151803_B65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","unstructured":"65. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovascular imaging. 2010;3(2):155-64.","journal-title":"JACC Cardiovascular imaging"},{"issue":"2","key":"key20210921151803_B66","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1161\/01.CIR.0000153623.02240.20","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Kwong","year":"2005","unstructured":"66. Kwong RY, Falk RH. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):122-4.","journal-title":"Circulation"},{"issue":"2","key":"key20210921151803_B67","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira","year":"2005","unstructured":"67. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186-93.","journal-title":"Circulation"},{"issue":"25","key":"key20210921151803_B68","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.jacc.2018.03.536","article-title":"Myocardial Edema and Prognosis in Amyloidosis","volume":"71","author":"Kotecha","year":"2018","unstructured":"68. Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, et al. Myocardial Edema and Prognosis in Amyloidosis. Journal of the American College of Cardiology. 2018;71(25):2919-31.","journal-title":"Journal of the American College of Cardiology"},{"issue":"11 Pt 2","key":"key20210921151803_B69","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","article-title":"Myocardial Amyloidosis: The Exemplar Interstitial Disease","volume":"12","author":"Fontana","year":"2019","unstructured":"69. Fontana M, Corovic A, Scully P, Moon JC. Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC Cardiovascular imaging. 2019;12(11 Pt 2):2345-56.","journal-title":"JACC Cardiovascular imaging"},{"issue":"9","key":"key20210921151803_B70","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jcmg.2012.04.006","article-title":"Quantification of extracellular matrix expansion by CMR in infiltrative heart disease","volume":"5","author":"Mongeon","year":"2012","unstructured":"70. Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovascular imaging. 2012;5(9):897-907.","journal-title":"JACC Cardiovascular imaging"},{"issue":"1","key":"key20210921151803_B71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study","volume":"6","author":"Banypersad","year":"2013","unstructured":"71. Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circulation Cardiovascular imaging. 2013;6(1):34-9.","journal-title":"Circulation Cardiovascular imaging"},{"issue":"5","key":"key20210921151803_B72","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and Extracellular Volume in Transthyretin Amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","unstructured":"72. Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. Native T1 and Extracellular Volume in Transthyretin Amyloidosis. JACC Cardiovascular imaging. 2019;12(5):810-9.","journal-title":"JACC Cardiovascular imaging"},{"issue":"2","key":"key20210921151803_B73","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","unstructured":"73. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovascular imaging. 2014;7(2):157-65.","journal-title":"JACC Cardiovascular imaging"},{"issue":"2","key":"key20210921151803_B74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","article-title":"Cardiovascular magnetic resonance for amyloidosis","volume":"20","author":"Fontana","year":"2015","unstructured":"74. Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015;20(2):133-44.","journal-title":"Heart Fail Rev"},{"issue":"1 Pt 1","key":"key20210921151803_B75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis","volume":"13","author":"Baggiano","year":"2020","unstructured":"75. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020;13(1 Pt 1):69-80.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"21","key":"key20210921151803_B76","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/heartjnl-2014-305710","article-title":"Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis","volume":"100","author":"Pozo","year":"2014","unstructured":"76. Pozo E, Kanwar A, Deochand R, Castellano JM, Naib T, Pazos-Lopez P, et al. Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. Heart. 2014;100(21):1688-95.","journal-title":"Heart"},{"issue":"8","key":"key20210921151803_B77","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ehjci\/jeaa063","article-title":"Multimodality imaging in cardiac amyloidosis: a primer for cardiologists","volume":"21","author":"Jurcut","year":"2020","unstructured":"77. Jurcut R, Onciul S, Adam R, Stan C, Coriu D, Rapezzi C, et al. Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. European heart journal cardiovascular Imaging. 2020;21(8):833-44.","journal-title":"European heart journal cardiovascular Imaging"},{"issue":"11","key":"key20210921151803_B78","doi-asserted-by":"crossref","first-page":"e 1","DOI":"10.1016\/j.cardfail.2019.08.001","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging","volume":"25","author":"Dorbala","year":"2019","unstructured":"78. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. J Card Fail.2019;25(11):e 1-e39.","journal-title":"J Card Fail"},{"key":"key20210921151803_B79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12872-016-0311-6","article-title":"Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis","volume":"16","author":"Zhao","year":"2016","unstructured":"79. Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Dis. 2016;16:129.","journal-title":"BMC Cardiovasc Dis"},{"issue":"16","key":"key20210921151803_B80","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis","volume":"132","author":"Fontana","year":"2015","unstructured":"80. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132(16):1570-9.","journal-title":"Circulation"},{"issue":"6","key":"key20210921151803_B81","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcmg.2015.10.027","article-title":"LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis","volume":"9","author":"Boynton","year":"2016","unstructured":"81. Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, et al. LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis. JACC Cardiovascular imaging. 2016;9(6):680-6.","journal-title":"JACC Cardiovascular imaging"},{"issue":"1","key":"key20210921151803_B82","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12968-017-0419-6","article-title":"The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. Journal of cardiovascular magnetic resonance","volume":"20","author":"Lin","year":"2018","unstructured":"82. Lin L, Li X, Feng J, Shen KN, Tian Z, Sun J, et al. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. Journal of cardiovascular magnetic resonance . J Cardiovasc Magn Reson. 2018;20(1):2.","journal-title":"J Cardiovasc Magn Reson"},{"key":"key20210921151803_B83","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1532-429X-14-88","article-title":"Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR","volume":"14","author":"Fontana","year":"2012","unstructured":"83. Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. Journal of cardiovascular magnetic resonance : J Cardiovasc Magn Reson. 2012;14:88.","journal-title":"Journal of cardiovascular magnetic resonance : J Cardiovasc Magn Reson"},{"issue":"2","key":"key20210921151803_B84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2013.09.019","article-title":"CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis","volume":"7","author":"White","year":"2014","unstructured":"84. White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):143-56.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"key20210921151803_B85","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to Image Cardiac Amyloidosis: A Practical Approach","volume":"13","author":"Dorbala","year":"2020","unstructured":"85. Dorbala S, Cuddy S, Falk RH. How to Image Cardiac Amyloidosis: A Practical Approach. JACC Cardiovascular imaging. 2020;13(6):1299-310.","journal-title":"JACC Cardiovascular imaging"},{"issue":"6","key":"key20210921151803_B86","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","article-title":"Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis","volume":"13","author":"Pan","year":"2020","unstructured":"86. Pan JA, Kerwin MJ, Salerno M. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis. JACC Cardiovascular imaging. 2020;13(6):1299-310.","journal-title":"JACC Cardiovascular imaging"},{"issue":"1","key":"key20210921151803_B87","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","article-title":"State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis","volume":"26","author":"Singh","year":"2019","unstructured":"87. Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol. 2019;26(1):158-73.","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"key20210921151803_B88","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","article-title":"Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis","volume":"25","author":"Stats","year":"2016","unstructured":"88. Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol. 2016;25(5):413-7.","journal-title":"Cardiovasc Pathol"},{"issue":"6","key":"key20210921151803_B89","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","unstructured":"89. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076-84.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20210921151803_B90","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","unstructured":"90. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26(6):2065-123.","journal-title":"J Nucl Cardiol"},{"issue":"22","key":"key20210921151803_B91","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week","volume":"75","author":"Hanna","year":"2020","unstructured":"91. Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, et al. Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(22):2851-62.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"key20210921151803_B92","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt","year":"2014","unstructured":"92. Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289-98.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"key20210921151803_B93","first-page":"284","article-title":"Binding of serum amyloid P-component (SAP) by amyloid fibrils","volume":"38","author":"Pepys","year":"1979","unstructured":"93. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 1979;38(2):284-93.","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"key20210921151803_B94","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis","volume":"1","author":"Castano","year":"2016","unstructured":"94. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol. 2016;1(8):880-9.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"key20210921151803_B95","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s12350-016-0768-9","article-title":"Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes","volume":"25","author":"Vranian","year":"2018","unstructured":"95. Vranian MN, Sperry BW, Hanna M, Hachamovitch R, Ikram A, Brunken RC, et al. Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes. J Nucl Cardiol. 2018;25(4):1247-56.","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"key20210921151803_B96","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12872-018-0952-8","article-title":"Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers","volume":"18","author":"Kyriakou","year":"2018","unstructured":"96. Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, et al. Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord. 2018;18(1):221.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"key20210921151803_B97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173086","article-title":"Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)","volume":"12","author":"Kristen","year":"2017","unstructured":"97. Kristen AV, Maurer MS, Rapezzi C, Mundayat R, Suhr OB, Damy T, et al. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS One. 2017;12(4):e0173086.","journal-title":"PLoS One"},{"issue":"11","key":"key20210921151803_B98","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2459\/JCM.0000000000000349","article-title":"Different NT-proBNP circulating levels for different types of cardiac amyloidosis","volume":"17","author":"Perfetto","year":"2016","unstructured":"98. Perfetto F, Bergesio F, Grifoni E, Fabbri A, Ciuti G, Frusconi S, et al. Different NT-proBNP circulating levels for different types of cardiac amyloidosis. J Cardiovasc Med (Hagerstown). 2016;17(11):810-7.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"9","key":"key20210921151803_B99","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis","volume":"8","author":"Hahn","year":"2020","unstructured":"99. Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, et al. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail. 2020;8(9):712-24.","journal-title":"JACC Heart Fail"},{"issue":"14","key":"key20210921151803_B100","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jacc.2010.06.016","article-title":"Troponin elevation in heart failure prevalence, mechanisms, and clinical implications","volume":"56","author":"Kociol","year":"2010","unstructured":"100. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O\u2019Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56(14):1071-8.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210921151803_B101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2018","unstructured":"101. Takashio S, Yamamuro M, Izumiya Y, Hirakawa K, Marume K, Yamamoto M, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2018;5(1):27-35.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"key20210921151803_B102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40119-020-00169-4","article-title":"Diagnosis of Transthyretin Amyloid Cardiomyopathy","volume":"9","author":"Hafeez","year":"2020","unstructured":"102. Hafeez AS, Bavry AA. Diagnosis of Transthyretin Amyloid Cardiomyopathy. Cardiol Ther. 2020;9(1):85-95.","journal-title":"Cardiol Ther"},{"issue":"1","key":"key20210921151803_B103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar","year":"2011","unstructured":"103. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(1):57-65.","journal-title":"Am J Hematol"},{"issue":"11","key":"key20210921151803_B104","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","unstructured":"104. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317-25.","journal-title":"Leukemia"},{"issue":"1","key":"key20210921151803_B105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/anr.1780320114","article-title":"Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis","volume":"32","author":"Duston","year":"1989","unstructured":"105. Duston MA, Skinner M, Meenan RF, Cohen AS. Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum. 1989;32(1):82-5.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"key20210921151803_B106","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.21902","article-title":"Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice","volume":"54","author":"van","year":"2006","unstructured":"106. van G, II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54(6):2015-21.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"key20210921151803_B107","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.4065\/77.12.1287","article-title":"Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy","volume":"77","author":"Andrews","year":"2002","unstructured":"107. Andrews TR, Colon-Otero G, Calamia KT, Menke DM, Boylan KB, Kyle RA. Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy. Mayo Clin Proc. 2002;77(12):1287-90.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"key20210921151803_B108","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine","year":"2014","unstructured":"108. Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113(10):1723-7.","journal-title":"Am J Cardiol"},{"issue":"1","key":"key20210921151803_B109","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","unstructured":"109. Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018;25(1):62-7.","journal-title":"Amyloid"},{"issue":"24","key":"key20210921151803_B110","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","unstructured":"110. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957-9.","journal-title":"Blood"},{"issue":"6","key":"key20210921151803_B111","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis","volume":"13","author":"Musumeci","year":"2020","unstructured":"111. Musumeci MB, Cappelli F, Russo D, Tini G, Canepa M, Milandri A, et al. Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020;13(6):1314-21.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"key20210921151803_B112","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ehjci\/jey225","article-title":"Mechanisms of heart failure in transthyretin vs. light chain amyloidosis","volume":"20","author":"Binder","year":"2019","unstructured":"112. Binder C, Duca F, Stelzer PD, Nitsche C, Rettl R, Aschauer S, et al. Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. Eur Heart J Cardiovasc Imaging. 2019;20(5):512-24.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"key20210921151803_B113","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/08998280.2013.11929013","article-title":"Isolated atrial amyloidosis and the importance of molecular classification","volume":"26","author":"Podduturi","year":"2013","unstructured":"113. Podduturi V, Armstrong DR, Hitchcock MA, Roberts WC, Guileyardo JM. Isolated atrial amyloidosis and the importance of molecular classification. Proc (Bayl Univ Med Cent). 2013;26(4):387-9.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"9","key":"key20210921151803_B114","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ajh.25149","article-title":"Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment","volume":"93","author":"Gertz","year":"2018","unstructured":"114. Gertz MA. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol. 2018;93(9):1169-80.","journal-title":"Am J Hematol"},{"issue":"9","key":"key20210921151803_B115","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","unstructured":"115. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-95.","journal-title":"J Clin Oncol"},{"issue":"4","key":"key20210921151803_B116","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcmg.2009.11.013","article-title":"Prognostic significance of strain Doppler imaging in light-chain amyloidosis","volume":"3","author":"Koyama","year":"2010","unstructured":"116. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010;3(4):333-42.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"key20210921151803_B117","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.echo.2019.04.418","article-title":"Myocardial Stiffness by Intrinsic Cardiac Elastography in Patients with Amyloidosis: Comparison with Chamber Stiffness and Global Longitudinal Strain","volume":"32","author":"Pislaru","year":"2019","unstructured":"117. Pislaru C, Ionescu F, Alashry M, Petrescu I, Pellikka PA, Grogan M, et al. Myocardial Stiffness by Intrinsic Cardiac Elastography in Patients with Amyloidosis: Comparison with Chamber Stiffness and Global Longitudinal Strain. J Am Soc Echocardiogr. 2019;32(8):958-68 e4.","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"key20210921151803_B118","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1161\/CIRCIMAGING.113.001144","article-title":"Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis","volume":"7","author":"Kuruvilla","year":"2014","unstructured":"118. Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7(2):250-8.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"key20210921151803_B119","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jcmg.2016.01.036","article-title":"Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis","volume":"9","author":"Raina","year":"2016","unstructured":"119. Raina S, Lensing SY, Nairooz RS, Pothineni NV, Hakeem A, Bhatti S, et al. Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis. JACC Cardiovasc Imaging. 2016;9(11):1267-77.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"key20210921151803_B120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","unstructured":"120. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244-51.","journal-title":"Eur Heart J"},{"issue":"13","key":"key20210921151803_B121","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","unstructured":"121. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12.","journal-title":"Circulation"},{"issue":"14","key":"key20210921151803_B122","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","unstructured":"122. Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020;41(14):1439-47.","journal-title":"Eur Heart J"},{"issue":"1","key":"key20210921151803_B123","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","unstructured":"123. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28(1):10-21.","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"key20210921151803_B124","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00392-019-01515-w","article-title":"Association of heart failure duration with clinical prognosis in advanced heart failure","volume":"109","author":"Sugiura","year":"2020","unstructured":"124. Sugiura A, Kitahara H, Iwahana T, Suzuki N, Okada S, Miyauchi H, et al. Association of heart failure duration with clinical prognosis in advanced heart failure. Clin Res Cardiol. 2020;109(3):350-7.","journal-title":"Clin Res Cardiol"},{"issue":"6-7","key":"key20210921151803_B125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejheart.2007.01.012","article-title":"Non-invasive predictors of survival in cardiac amyloidosis","volume":"9","author":"Kristen","year":"2007","unstructured":"125. Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007;9(6-7):617-24.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"key20210921151803_B126","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","unstructured":"126. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"key20210921151803_B127","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","unstructured":"127. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-72.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"key20210921151803_B128","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","volume":"68","author":"Grogan","year":"2016","unstructured":"128. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016;68(10):1014-20.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20210921151803_B129","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin","volume":"11","author":"Hanson","year":"2018","unstructured":"129. Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, et al. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ Heart Fail. 2018;11(2):e004000.","journal-title":"Circ Heart Fail"},{"issue":"30","key":"key20210921151803_B130","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","unstructured":"130. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-806.","journal-title":"Eur Heart J"},{"issue":"3","key":"key20210921151803_B131","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.cjca.2019.12.020","article-title":"Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems","volume":"36","author":"Cappelli","year":"2020","unstructured":"131. Cappelli F, Martone R, Gabriele M, Taborchi G, Morini S, Vignini E, et al. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. Can J Cardiol. 2020;36(3):424-31.","journal-title":"Can J Cardiol"},{"issue":"8","key":"key20210921151803_B132","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cardfail.2018.07.001","article-title":"Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis","volume":"24","author":"Rubin","year":"2018","unstructured":"132. Rubin J, Steidley DE, Carlsson M, Ong ML, Maurer MS. Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis. J Card Fail. 2018;24(8):504-11.","journal-title":"J Card Fail"},{"issue":"10","key":"key20210921151803_B133","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/heartjnl-2015-308657","article-title":"Prognostic implication of relative regional strain ratio in cardiac amyloidosis","volume":"102","author":"Senapati","year":"2016","unstructured":"133. Senapati A, Sperry BW, Grodin JL, Kusunose K, Thavendiranathan P, Jaber W, et al. Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart. 2016;102(10):748-54.","journal-title":"Heart"},{"issue":"5","key":"key20210921151803_B134","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles","volume":"12","author":"Knight","year":"2019","unstructured":"134. Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, et al. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. JACC Cardiovasc Imaging. 2019;12(5):823-33.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"23","key":"key20210921151803_B135","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","unstructured":"135. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620-7.","journal-title":"Blood"},{"issue":"36","key":"key20210921151803_B136","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","unstructured":"136. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-9.","journal-title":"J Clin Oncol"},{"issue":"2","key":"key20210921151803_B137","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","unstructured":"137. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014;99(2):209-21.","journal-title":"Haematologica"},{"issue":"15","key":"key20210921151803_B138","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","unstructured":"138. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325-32.","journal-title":"Blood"},{"issue":"1","key":"key20210921151803_B139","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","unstructured":"139. Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71-80.","journal-title":"Blood"},{"issue":"7","key":"key20210921151803_B140","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bmt.2015.73","article-title":"Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation","volume":"50","author":"Cornell","year":"2015","unstructured":"140. Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, et al. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant. 2015;50(7):914-7.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"key20210921151803_B141","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","unstructured":"141. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083-93.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20210921151803_B142","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","article-title":"Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients","volume":"101","author":"Moreau","year":"1998","unstructured":"142. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101(4):766-9.","journal-title":"Br J Haematol"},{"issue":"10","key":"key20210921151803_B143","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","unstructured":"143. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91(10):3662-70.","journal-title":"Blood"},{"issue":"24","key":"key20210921151803_B144","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1002\/cncr.27660","article-title":"Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis","volume":"118","author":"Cordes","year":"2012","unstructured":"144. Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer. 2012;118(24):6105-9.","journal-title":"Cancer"},{"issue":"1","key":"key20210921151803_B145","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2016.229","article-title":"Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis","volume":"31","author":"Landau","year":"2017","unstructured":"145. Landau H, Smith M, Landry C, Chou JF, Devlin SM, Hassoun H, et al. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia. 2017;31(1):136-42.","journal-title":"Leukemia"},{"issue":"20","key":"key20210921151803_B146","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","unstructured":"146. Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126(20):2345-7.","journal-title":"Blood"},{"issue":"13","key":"key20210921151803_B147","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time","volume":"36","author":"Sidiqi","year":"2018","unstructured":"147. Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. J Clin Oncol. 2018;36(13):1323-9.","journal-title":"J Clin Oncol"},{"issue":"4","key":"key20210921151803_B148","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","unstructured":"148. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557-61.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"key20210921151803_B149","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.11413","article-title":"Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response","volume":"92","author":"Gertz","year":"2007","unstructured":"149. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007;92(10):1415-8.","journal-title":"Haematologica"},{"issue":"34","key":"key20210921151803_B150","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","unstructured":"150. Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31(34):4319-24.","journal-title":"J Clin Oncol"},{"issue":"19","key":"key20210921151803_B151","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","unstructured":"151. Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-90.","journal-title":"Blood"},{"issue":"19","key":"key20210921151803_B152","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","unstructured":"152. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4.","journal-title":"Blood"},{"issue":"5","key":"key20210921151803_B153","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","unstructured":"153. Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612-5.","journal-title":"Blood"},{"issue":"9","key":"key20210921151803_B154","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"Jaccard","year":"2014","unstructured":"154. Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99(9):1479-85.","journal-title":"Haematologica"},{"issue":"4","key":"key20210921151803_B155","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1002\/ajh.23936","article-title":"Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies","volume":"90","author":"Kastritis","year":"2015","unstructured":"155. Kastritis E, Roussou M, Gavriatopoulou M, Migkou M, Kalapanida D, Pamboucas C, et al. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015;90(4):E60-5.","journal-title":"Am J Hematol"},{"issue":"28","key":"key20210921151803_B156","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis","volume":"38","author":"Kastritis","year":"2020","unstructured":"156. Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. J Clin Oncol. 2020;38(28):3252-60.","journal-title":"J Clin Oncol"},{"issue":"3","key":"key20210921151803_B157","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","article-title":"Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)","volume":"40","author":"Holmgren","year":"1991","unstructured":"157. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40(3):242-6.","journal-title":"Clin Genet"},{"issue":"4","key":"key20210921151803_B158","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","article-title":"Progression of transthyretin amyloid neuropathy after liver transplantation","volume":"75","author":"Liepnieks","year":"2010","unstructured":"158. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324-7.","journal-title":"Neurology"},{"issue":"4","key":"key20210921151803_B159","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/13506129.2011.615872","article-title":"Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients","volume":"18","author":"Okamoto","year":"2011","unstructured":"159. Okamoto S, Zhao Y, Lindqvist P, Backman C, Ericzon BG, Wijayatunga P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid. 2011;18(4):200-5.","journal-title":"Amyloid"},{"issue":"2","key":"key20210921151803_B160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejcts.2007.10.025","article-title":"Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis","volume":"33","author":"Sack","year":"2008","unstructured":"160. Sack FU, Kristen A, Goldschmidt H, Schnabel PA, Dengler T, Koch A, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg. 2008;33(2):257-62.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"24","key":"key20210921151803_B161","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","unstructured":"161. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629-34.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"key20210921151803_B162","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","unstructured":"162. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785-92.","journal-title":"Neurology"},{"issue":"11","key":"key20210921151803_B163","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","unstructured":"163. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-16.","journal-title":"N Engl J Med"},{"key":"key20210921151803_B164","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","author":"Damy","year":"2020","unstructured":"164. Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2020.","journal-title":"Eur J Heart Fail"},{"key":"key20210921151803_B165","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity","volume":"99","author":"Hammarstrom","year":"2002","unstructured":"165. Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A. 2002;99 Suppl 4:16427-32.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"key20210921151803_B166","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy","volume":"74","author":"Judge","year":"2019","unstructured":"166. Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285-95.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20210921151803_B167","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","unstructured":"167. Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11-21.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20210921151803_B168","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","unstructured":"168. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22-31.","journal-title":"N Engl J Med"},{"issue":"45","key":"key20210921151803_B169","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","unstructured":"169. Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferovic PM, et al. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J. 2019;40(45):3699-706.","journal-title":"Eur Heart J"},{"issue":"2","key":"key20210921151803_B170","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","unstructured":"170. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006;20(2):234-9.","journal-title":"FASEB J"},{"key":"key20210921151803_B171","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","unstructured":"171. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74.","journal-title":"J Transl Med"},{"issue":"2","key":"key20210921151803_B172","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.hfc.2016.12.003","article-title":"Current concepts of cardiac amyloidosis: diagnosis, clinical management, and the need for collaboration","volume":"13","author":"Ritts","year":"2017","unstructured":"172. Ritts AJ, Cornell RF, Swiger K, Singh J, Goodman S, Lenihan DJ. Current concepts of cardiac amyloidosis: diagnosis, clinical management, and the need for collaboration. Heart Failure Clinics. 2017;13(2):409-16.","journal-title":"Heart Failure Clinics"},{"issue":"2","key":"key20210921151803_B173","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","unstructured":"173. Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest. 1993;104(2):618-20.","journal-title":"Chest"},{"issue":"3","key":"key20210921151803_B174","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","unstructured":"174. Sanchis K, Cariou E, Colombat M, Ribes D, Huart A, Cintas P, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid. 2019;26(3):128-38.","journal-title":"Amyloid"},{"issue":"3","key":"key20210921151803_B175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","unstructured":"175. Longhi S, Quarta CC, Milandri A, Lorenzini M, Gagliardi C, Manuzzi L, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015;22(3):147-55.","journal-title":"Amyloid"},{"issue":"5","key":"key20210921151803_B176","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","unstructured":"176. Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC heart failure. 2018;5(5):772-9.","journal-title":"ESC heart failure"},{"issue":"2","key":"key20210921151803_B177","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis","volume":"22","author":"Donnellan","year":"2020","unstructured":"177. Donnellan E, Wazni O, Kanj M, Elshazly MB, Hussein A, Baranowski B, et al. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. EP Europace. 2020;22(2):259-64.","journal-title":"EP Europace"},{"issue":"1","key":"key20210921151803_B178","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0002-9149(83)90084-X","article-title":"Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients","volume":"52","author":"Roberts","year":"1983","unstructured":"178. Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. The American journal of cardiology. 1983;52(1):137-46.","journal-title":"The American journal of cardiology"},{"issue":"21","key":"key20210921151803_B179","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","unstructured":"179. Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116(21):2420-6.","journal-title":"Circulation"},{"issue":"18","key":"key20210921151803_B180","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","unstructured":"180. Feng D, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009;119(18):2490.","journal-title":"Circulation"},{"issue":"12","key":"key20210921151803_B181","first-page":"1473","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","unstructured":"181. Donnellan E, Elshazly MB, Vakamudi S, Wazni OM, Cohen JA, Kanj M, et al. No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC: Clinical Electrophysiology. 2019;5(12):1473-4.","journal-title":"JACC: Clinical Electrophysiology"},{"issue":"5","key":"key20210921151803_B182","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","unstructured":"182. El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. Journal of the American College of Cardiology. 2019;73(5):589-97.","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"key20210921151803_B183","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2009.05.040","article-title":"Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring","volume":"104","author":"Goldsmith","year":"2009","unstructured":"183. Goldsmith YB, Liu J, Chou J, Hoffman J, Comenzo RL, Steingart RM. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. The American journal of cardiology. 2009;104(7):990-4.","journal-title":"The American journal of cardiology"},{"issue":"8","key":"key20210921151803_B184","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1460-9592.2001.01228.x","article-title":"Holter monitoring in AL amyloidosis: prognostic implications","volume":"24","author":"Palladini","year":"2001","unstructured":"184. Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing and Clinical Electrophysiology. 2001;24(8):1228-33.","journal-title":"Pacing and Clinical Electrophysiology"},{"issue":"11","key":"key20210921151803_B185","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","author":"Towbin","year":"2019","unstructured":"185. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FC, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart rhythm. 2019;16(11):e301-e72.","journal-title":"Heart rhythm"},{"issue":"11","key":"key20210921151803_B186","first-page":"1601","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"17","author":"Members","year":"2015","unstructured":"186. Members ATF, Priori SG, Blomstr\u00f6m-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Ep Europace. 2015;17(11):1601-87.","journal-title":"Ep Europace"},{"key":"key20210921151803_B187","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.carrev.2020.06.005","article-title":"Cardiac Amyloidosis in Patients Undergoing TAVR: Why We Need to Think About It","volume":"22","author":"Cappelli","year":"2021","unstructured":"187. Cappelli F, Perfetto F, Martone R, Di Mario C. Cardiac Amyloidosis in Patients Undergoing TAVR: Why We Need to Think About It. Cardiovascular Revascularization Medicine. 2021;22:109-14.","journal-title":"Cardiovascular Revascularization Medicine"},{"issue":"18","key":"key20210921151803_B188","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","unstructured":"188. Sayed RH, Rogers D, Khan F, Wechalekar AD, Lachmann HJ, Fontana M, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. European heart journal. 2015;36(18):1098-105.","journal-title":"European heart journal"},{"issue":"4","key":"key20210921151803_B189","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","unstructured":"189. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. Clinical Electrophysiology. 2020;6(4):351-61.","journal-title":"Clinical Electrophysiology"},{"issue":"5","key":"key20210921151803_B190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0002-9343(77)90870-1","article-title":"The conduction system in cardiac amyloidosis: clinical and pathologic features of 23 patients","volume":"62","author":"Ridolfi","year":"1977","unstructured":"190. Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis: clinical and pathologic features of 23 patients. The American journal of medicine. 1977;62(5):677-86.","journal-title":"The American journal of medicine"},{"issue":"12","key":"key20210921151803_B191","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.healun.2012.09.018","article-title":"Outcomes of adults with restrictive cardiomyopathy after heart transplantation","volume":"31","author":"DePasquale","year":"2012","unstructured":"191. DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. The Journal of heart and lung transplantation. 2012;31(12):1269-75.","journal-title":"The Journal of heart and lung transplantation"},{"issue":"2","key":"key20210921151803_B192","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/ahe.13.10","article-title":"Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center","volume":"9","author":"Givens","year":"2013","unstructured":"192. Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging health. 2013;9(2):229-35.","journal-title":"Aging health"},{"issue":"3","key":"key20210921151803_B193","first-page":"266","article-title":"Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy","volume":"4","author":"Topilsky","year":"2011","unstructured":"193. Topilsky Y, Pereira NL, Shah DK, Boilson B, Schirger JA, Kushwaha SS, et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circulation: Heart Failure. 2011;4(3):266-75.","journal-title":"Circulation: Heart Failure"},{"issue":"8","key":"key20210921151803_B194","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2015.03.012","article-title":"Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease","volume":"34","author":"Grupper","year":"2015","unstructured":"194. Grupper A, Park SJ, Pereira NL, Schettle SD, Gerber Y, Topilsky Y, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. The Journal of Heart and Lung Transplantation. 2015;34(8):1042-9.","journal-title":"The Journal of Heart and Lung Transplantation"},{"issue":"5","key":"key20210921151803_B195","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","unstructured":"195. Kristen AV, Kreusser MM, Blum P, Sch\u00f6nland SO, Frankenstein L, D\u00f6sch AO, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. The journal of heart and lung transplantation. 2018;37(5):611-8.","journal-title":"The journal of heart and lung transplantation"},{"issue":"10","key":"key20210921151803_B196","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1111\/ajt.15487","article-title":"Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis","volume":"19","author":"Trachtenberg","year":"2019","unstructured":"196. Trachtenberg BH, Kamble RT, Rice L, Araujo-Gutierrez R, Bhimaraj A, Guha A, et al. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. American Journal of Transplantation. 2019;19(10):2900-9.","journal-title":"American Journal of Transplantation"},{"key":"key20210921151803_B197","article-title":"Incorpora\u00e7\u00f5es de medicamentos para doen\u00e7as raras no Brasil: \u00e9 poss\u00edvel acesso integral a estes pacientes?","author":"Biglia","year":"2020","unstructured":"197. Biglia LV, Mendes SJ, Lima TM, Aguiar PM. Incorpora\u00e7\u00f5es de medicamentos para doen\u00e7as raras no Brasil: \u00e9 poss\u00edvel acesso integral a estes pacientes? Cien Sa\u00fade Colet. 2020(julho\/2020 - Est\u00e1 dispon\u00edvel em: http:\/\/www.cienciaesaudecoletiva.com.br\/artigos\/incorporacoes-de-medicamentos-para-doencas-raras-no-brasil-e-possivel-acesso-integral-a-estes-pacientes\/17706?id=17706&id=17706).","journal-title":"Cien Sa\u00fade Colet"},{"issue":"3","key":"key20210921151803_B198","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1590\/0102-311x00213813","article-title":"Economic evaluation in the context of rare diseases: is it possible?","volume":"31","author":"Silva","year":"2015","unstructured":"198. Silva EN, Sousa TR. Economic evaluation in the context of rare diseases: is it possible? Cad Saude Publica. 2015;31(3):496-506.","journal-title":"Cad Saude Publica"},{"key":"key20210921151803_B199","first-page":"199","article-title":"Pol\u00edtica Nacional de Aten\u00e7\u00e3o Integral \u00e0s Pessoas com Doen\u00e7as Raras","author":"Brasil. Minist\u00e9rio da Sa\u00fade","unstructured":"199. Brasil. Minist\u00e9rio da Sa\u00fade. Pol\u00edtica Nacional de Aten\u00e7\u00e3o Integral \u00e0s Pessoas com Doen\u00e7as Raras. Portaria GM n\u00ba 199, de 30 de janeiro de 2014. Dispon\u00edvel em: http:\/\/bvsmssaudegovbr\/bvs\/saudelegis\/gm\/2014\/prt0199_30_01_2014html.","journal-title":"Portaria GM n\u00ba"},{"key":"key20210921151803_B200","article-title":"Doen\u00e7as Raras: A urg\u00eancia do acesso \u00e0 sa\u00fade","author":"INTERFARMA","year":"2018","unstructured":"200. INTERFARMA. Doen\u00e7as Raras: A urg\u00eancia do acesso \u00e0 sa\u00fade. Fevereiro de 2018. Dispon\u00edvel em: https:\/\/www.interfarma.org.br\/public\/files\/biblioteca\/doencas-raras--a-urgencia-do-acesso-a-saude-interfarma.pdf. Acesso em: 14 abr. 2019.","journal-title":"Fevereiro de"},{"issue":"5","key":"key20210921151803_B201","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1590\/15174522-0215121","article-title":"Doen\u00e7as raras, drogas \u00f3rf\u00e3s e as pol\u00edticas para avalia\u00e7\u00e3o e incorpora\u00e7\u00e3o de tecnologias nos sistemas de sa\u00fade","volume":"21","author":"Novaes","year":"2019","unstructured":"201. Novaes HMD, So\u00e1rez PC. Doen\u00e7as raras, drogas \u00f3rf\u00e3s e as pol\u00edticas para avalia\u00e7\u00e3o e incorpora\u00e7\u00e3o de tecnologias nos sistemas de sa\u00fade. Sociologias. 2019;21(5):332-64.","journal-title":"Sociologias"},{"issue":"2","key":"key20210921151803_B202","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.healthpol.2017.03.009","article-title":"HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries","volume":"123","author":"Nicod","year":"2019","unstructured":"202. Nicod E, Annemans L, Bucsics A, Lee A, Upadhyaya S, Facey K. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries. Health Policy. 2019;123(2):140-51.","journal-title":"Health Policy"},{"issue":"7","key":"key20210921151803_B203","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","article-title":"Detection of cardiac amyloidosis with (18)F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy","volume":"46","author":"Kircher","year":"2019","unstructured":"203. Kircher M, Ihne S, Brumberg J, Morbach C, Knop S, Kortum KM, et al. Detection of cardiac amyloidosis with (18)F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging. 2019;46(7):1407-16.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"key20210921151803_B204","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s12350-017-0799-x","article-title":"(18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis","volume":"25","author":"Morgenstern","year":"2018","unstructured":"204. Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. (18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2018;25(5):1559-67.","journal-title":"J Nucl Cardiol"},{"key":"key20210921151803_B205","first-page":"60","article-title":"Biomarkers in Immunoglobulin Light Chain Amyloidosis","volume":"30","author":"Kufova","unstructured":"205. Kufova Z, Sevcikova T, Growkova K, Vojta P, Filipova J, Adam Z, et al. Biomarkers in Immunoglobulin Light Chain Amyloidosis. Klin Onkol.30(Suppl 2):60-7.","journal-title":"Klin Onkol"},{"issue":"24","key":"key20210921151803_B206","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1182\/blood-2015-10-673095","article-title":"Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis","volume":"127","author":"Paiva","year":"2016","unstructured":"206. Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127(24):3035-9.","journal-title":"Blood"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/abccardiol.org\/article\/posicionamento-sobre-diagnostico-e-tratamento-da-amiloidose-cardiaca-2021\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:06:25Z","timestamp":1747400785000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/posicionamento-sobre-diagnostico-e-tratamento-da-amiloidose-cardiaca-2021\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":206,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9,1]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.36660\/abc.20210718"],"URL":"https:\/\/doi.org\/10.36660\/abc.20210718","relation":{},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"value":"0066-782X","type":"print"},{"value":"1678-4170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}